{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.883","upperLimit":"3.18","value":"2.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (time)","dispersionType":"Full Range","groups":[{"description":"Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.","id":"OG000","title":"Asciminib (All Asciminib)"}],"paramType":"MEDIAN","populationDescription":"Full PK samples were collected at Week 2","reportingStatus":"POSTED","timeFrame":"Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)","title":"PK of Asciminib: Tmax","type":"SECONDARY","unitOfMeasure":"Hour (hr)"}